Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development-Reference-Cited by-同舟云学术

Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development

Published:2016-09-15 Issue:2 Volume:10 Page:203-213
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Copley-Merriman Catherine,Zelt Susan,Clark Marci,Gnanasakthy Ari

Funder

GlaxoSmithKline

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s40271-016-0196-6.pdf

Reference48 articles.

1. Hollestein LM, Nijsten T. An insight into the global burden of skin diseases. J Invest Dermatol. 2014;134:1499–501.

2. Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134:1527–34.

3. Ahmed A, Leon A, Butler DC, Reichenberg J. Quality-of-life effects of common dermatological diseases. Semin Cutan Med Surg. 2013;32:101–9.

4. Townshend A, Chen C-M, Williams H. How prominent are patient-reported outcomes in clinical trials of dermatological treatments? Br J Dermatol. 2008;159:1152–9.

5. Food and Drug Administration (FDA). Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Dec 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf . Accessed 16 Nov 2015.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study;Journal of Dermatological Treatment;2024-05-02

2. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2);Dermatology and Therapy;2024-05

3. Medidas de resultados comunicados por el paciente para evaluar la dermatitis atópica;Farmacia Hospitalaria;2024-05

4. Safety, Efficacy and Attributes of 2.5% Selenium Sulfide Shampoo in the Treatment of Dandruff: A Single-Center Study;Cureus;2024-03-28

5. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2);American Journal of Clinical Dermatology;2024-03-25